Alnylam Pharmace. buy StockNews.com
Start price
06.05.23
/
50%
€193.40
Target price
06.05.24
-
Performance (%)
-26.81%
End price
07.05.24
€141.55
Summary
This prediction ended on 07.05.24 with a price of €141.55. The prediction for Alnylam Pharmace. disappointed with a performance of -26.81%. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 6.222% | 6.222% | -6.696% | 45.650% |
| iShares Core DAX® | -0.388% | -1.791% | 5.613% | 55.044% |
| iShares Nasdaq 100 | -2.403% | 0.855% | 36.018% | 91.177% |
| iShares Nikkei 225® | -0.817% | 8.951% | 67.624% | 85.346% |
| iShares S&P 500 | -1.045% | -0.077% | 24.987% | 67.530% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten